Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, ...

What if you lost weight and didn’t care — about anything?

Eli Lilly unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows.

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think ...

Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.

Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans ...

At $16, Hims & Hers Health stock is cheap on sales metrics, but upside is capped pending regulatory clarity and proof of profit pool rebuild. Read why HIMS is a Hold.

Popular GLP-1 weight-loss medications have helped millions of people shed pounds, but new research from Australia.

Researchers have discovered that drugs like Ozempic for diabetes and obesity also improve alcohol use disorders and other ...